IMBiologics (IMB) focuses on developing novel treatment options for Immunology & inflammation (I&I) diseases and cancer, utilizing innovative mechanisms of action and/or multivalent antibody platform technology, ePENDY. 

Given IMB’s successful out-licensing experience of our lead asset, IMB-101, a bispecific antibody targeting OX40L and TNFα in 2024, IMB focuses on two areas: Immuno-oncology and auto-immunity & inflammation with new modalities, including bi-specific antibody and ePENDY. 

IMBiologics Corp.

Org chart

Teams

Offices

IMBiologics Corp.

Org chart

Teams

Offices

Related companies